Zeltia
Zeltia is a former Spanish pharmaceutical company which operated through a variety of subsidiaries in the pharmaceutical and chemical industries. As of 2007, Zeltia's research activities in the pharmaceutical area had not resulted in a marketed product.[history 2] However, the company's majority shareholder and chairman are the same person, which has relieved the pressure which many CEOs have experienced to produce immediate returns.[history 3] HistoryIn 1993 Zeltia sells its subsidiary Cooper-Zeltia taking the name CZ Veterinaria, which years later would be renamed Zendal.[1] The company was taken over by its subsidiary Pharma Mar in a reverse takeover, keeping the Zeltia's Group structure. In 2018 PharmaMar sells Xylazel to the Dutch company AkzoNobel.[2][3] In 2019 PharmaMar sells Zelnova, the group's last subsidiary in Galicia, to the Galician investment company Allentia Invest for 33 million euros.[4] SubsidiariesDirect subsidiaries as of 2009 were:[finan 2] Pharma Mar, S.A.U.; Genómica, S.A.U.; Zelnova, S.A; Protección de Maderas, S.A.U; Xylazel, S.A.; Noscira, S.A.; Sylentis, S.A. Indirect subsidiaries which are direct subsidiaries of Pharma Mar as of 2009 were:[finan 2] Pharma Mar US; Pharma Mar AG; PharmaMar S.A.R.L.; Pharma Mar GmbH; Pharma Mar Ltd. A single indirect subsidiary is a direct subsidiary of Zelnova, that being Copyr, S.p.A.[finan 2] References
Financial
History
|